Syapse, a Palo Alto, CA-based company enabling healthcare systems to implement precision medicine programs has raised $25 million in Series C funding led by Ascension Ventures, a subsidiary of Ascension, the nation’s largest non-profit and Catholic health system. Existing investors Social Capital Partnership and Safeguard Scientifics also participated in this new funding round. The company will use this funding round to drive the rapid expansion of its Syapse Precision Medicine Platform in community health systems.
Precision medicine requires a better approach to health IT
Today, genomic and molecular data, such as tumor genome profiles, have become critical for diagnosing molecular subtypes of disease and for determining appropriate therapeutic interventions. Unfortunately, clinicians are increasingly overwhelmed when trying to incorporate these new data types into clinical decisions.
For providers, their EMRs and other IT systems lack the ability to handle the scale, volume, and complexity of genomic and molecular data. Understanding implications of genomic and molecular data is much more complex than for standard lab tests, requiring ever-changing interpretation, transformation of complex knowledge into actionable guidance, and continuous monitoring of outcomes.
Syapse Precision Medicine Platform Overview
– Integrating clinical, genomic, and other molecular data from medical records, labs, and pharmacies to see the full longitudinal profile of a patient
– Providing guidance on the appropriate diagnostic and therapeutic strategy, based on clinical best practices
– Implementing treatment decisions more effectively, and coordinating complex care across large, geographically dispersed care teams
– Rigorously measuring patient outcomes to rapidly learn what works and improve best practices
“Adoption of precision medicine by community providers and health systems is at an inflection point,” said Glenn Winokur, Syapse CEO in an official statement. “In addition to improving outcomes for the most critically ill patients, such as those with cancer, precision medicine is underpinning a shift toward value-based care. Over the coming year, we have extensive plans to enhance Syapse Precision Medicine Platform, including support for alternative payment models and expansion to new clinical service lines. Partnering with Ascension Ventures is a vote of confidence in our product and team, and a recognition that Syapse has become the partner of choice to leading community health systems in their transition to precision medicine.”
